Pfizer (NYSE:PFE) Stock Falls 2.9% – Should You Sell?

Shares of Pfizer Inc. (NYSE:PFE) were down 2.9% during trading on Thursday. The company traded as low as $29.85 and last traded at $29.9070. Approximately 52,544,898 shares traded hands during mid-day trading, an increase of 32% from the average session volume of 39,817,523 shares. The stock had previously closed at $30.79.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer raised its 2026 revenue outlook to $62 billion–$64 billion and adjusted EPS guidance to $2.95–$3.05. Non-COVID products grew 7% operationally in the quarter, while launched and acquired products rose 32%, reinforcing the company’s growth-beyond-COVID strategy. Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Guggenheim raised its price target to $33 and assigned a Buy rating, while unusually high call-option activity suggests some traders are positioning for upside. Options activity is speculative and does not guarantee a price move.
• Positive Sentiment: Pfizer advanced its Phase 3 study of a monthly obesity drug, a potential pipeline catalyst as investors assess its ability to compete in the weight-loss market. Pfizer Advances Monthly Obesity Drug Study
• Neutral Sentiment: Analyst views remain mixed: Goldman Sachs maintained a Hold rating, while UBS and Citi raised targets but kept Neutral ratings. Goldman Sachs Remains a Hold on Pfizer
• Negative Sentiment: Margin compression remains a concern, and investors may want evidence that new-product growth and cost reductions can translate into durable earnings improvement. That uncertainty could temper the positive impact of raised guidance. Pfizer Q3 deep dive

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on PFE shares. Guggenheim upped their price target on shares of Pfizer from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday. Citigroup lifted their price objective on shares of Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Wednesday. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. BMO Capital Markets cut their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Five analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $29.94.

Pfizer Stock Performance

The firm’s fifty day simple moving average is $28.69 and its 200 day simple moving average is $26.86. The company has a market capitalization of $170.46 billion, a PE ratio of 42.72, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. The business had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a return on equity of 19.98% and a net margin of 6.34%. The company’s revenue was down .4% on a year-over-year basis. During the same quarter last year, the business posted $0.87 EPS. On average, research analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. boosted its holdings in Pfizer by 15.7% during the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after buying an additional 745,213 shares in the last quarter. Handelsbanken Fonder AB grew its position in Pfizer by 10.4% during the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after buying an additional 232,528 shares during the period. Leuthold Group LLC purchased a new position in Pfizer in the second quarter valued at $4,887,000. Park National Corp OH increased its holdings in Pfizer by 332.1% in the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after buying an additional 186,053 shares in the last quarter. Finally, 111 Capital purchased a new position in Pfizer in the second quarter valued at $3,706,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.